特立氟胺片治疗中轴型脊柱关节炎的有效性和安全性的系统评价和 Meta 分析
Intravitreal slow-releasing dexamethasone implant for idiopathic neuroretinitis.
机构信息
Department of Ophthalmology, Marmara University School of Medicine, Istanbul, Turkey.
Department of Ophthalmology, Abdulkadir Yuksel Public Hospital, Gaziantep, Turkey.
出版信息
Eur J Ophthalmol. 2022 Jan;32(1):NP226-NP229. doi: 10.1177/1120672120953075. Epub 2020 Sep 3.
INTRODUCTION
The purpose of this report is to describe a successful management of idiopathic neuroretinitis with intravitreal dexamethasone implant.
METHOD
Interventional case report.
CLINICAL CASE
A 34-year-old man with an acute painless unilateral vision loss, optic disc swelling, and a macular edema was diagnosed as idiopathic neuroretinitis, and he underwent 0.7 mg dexamethasone intravitreous implant injection. Macular edema responded quickly and visual acuity improved from 20/50 to 20/25 within 2 weeks and to 20/20 within a month. One month after the injection, optic disc edema disappeared. No recurrence occurred and visual acuity was stable at 20/20 during 3 years of follow-up.
CONCLUSION
Idiopathic neuroretinitis can be treated with intravitreal dexamethasone implant.
简介
本报告旨在描述一例特发性神经炎伴黄斑水肿经玻璃体腔注射曲安奈德治疗成功的病例。
方法
介入性病例报告。
临床病例
一名 34 岁男性，因急性单侧无痛性视力丧失、视盘肿胀和黄斑水肿被诊断为特发性神经炎，给予 0.7mg 曲安奈德玻璃体腔注射。黄斑水肿迅速缓解，视力在 2 周内从 20/50 提高至 20/25，1 个月内提高至 20/20。注射后 1 个月，视盘水肿消失。随访 3 年无复发，视力稳定在 20/20。
结论
特发性神经炎可采用玻璃体腔注射曲安奈德治疗。
Zotero 插件